{"entity":{"id":"nct06144671","kind":"trial","name":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of GT201 in advanced solid tumours, run by Grit Biotechnology, now recruiting.","summary":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06144671 by Grit Biotechnology, with 78 participants planned, started 2025-11-01 and due to reach its primary completion in 2027-12-30. Interventions recorded: GT201, IL-2 and PD-1 inhibitor.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06144671","url":"https://clinicaltrials.gov/study/NCT06144671"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06144671","phase":"1/2","setting":"Phase I/II Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT201 Injection) as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","sponsor":"Grit Biotechnology","enrolled":78,"outcomes":[]},"route":"/trials/nct06144671/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}